Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
17,661,042
-
Shares change
-
-337,509
-
Total reported value, excl. options
-
$358,518,075
-
Value change
-
-$11,587,017
-
Number of buys
-
20
-
Number of sells
-
-22
-
Price
-
$20.30
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q1 2021
54 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q1 2021.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17,661,042 shares
of 274,772,727 outstanding shares and own 6.43% of the company stock.
Largest 10 shareholders include FMR LLC (5,664,215 shares), BlackRock Inc. (2,261,245 shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO (2,179,000 shares), FRANKLIN RESOURCES INC (1,119,169 shares), Artal Group S.A. (1,040,882 shares), Casdin Capital, LLC (820,440 shares), SANDS CAPITAL MANAGEMENT, LLC (724,873 shares), Alphabet Inc. (640,882 shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500,000 shares), and PERCEPTIVE ADVISORS LLC (470,440 shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.